NCT01228370

Efficacy and Safety of Silodosin on Voiding Dysfunction Associated With Neurogenic Bladder

A 12-week, Open-label, Multi-center Study to Evaluate the Clinical Efficacy and Safety of Silodosin on Voiding Dysfunction Associated With Neurogenic Bladder

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 95 (actual)
• Sponsor: JW Pharmaceutical · Industry
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

Because the bladder neck and proximal urethra contain abundant α1-adrenergic receptors, α-blockers or α1-blockers are well-known to reduce bladder neck obstruction in patients with or without neurogenic bladder. α1-blockers seem to have a potential to reduce bladder outlet resistance during voiding in patients with neurogenic bladder. Based on these turnouts, we designed this clinical study to evaluate the clinical effect and safety of silodosin on voiding dysfunction associated with neurogenic bladder.

Conditions

• Neurogenic Bladder
• Voiding Dysfunction

Interventions

Type	Name	Description
DRUG	silodosin	silodosin 8mg once a day for 12 weeks

Timeline

• Start date: 2011-04-01
• Primary completion: 2012-01-01
• Completion: 2012-01-01
• First posted: 2010-10-26
• Last updated: 2012-10-05

Locations

6 sites across 1 country: South Korea